




Claim 8. (Original) The method of claim 7 wherein the serine protease is a part of the TF/VIIa complex.

Claims 9-14 (Canceled).

Claim 15. (Presently Amended) A method for the treatment of prevention of a thrombolytic condition in a subject, the method comprising administering to the subject ~~the compound of claim 4~~ a compound having the structure:



or a pharmaceutically acceptable salt, prodrug, tautomer, or isomer thereof and a thrombolytic agent.

Claim 16. (Original) The method of claim 15 wherein the thrombolytic agent is selected from the group consisting of anti-platelet agents, anticoagulation agents and cardiovascular agents.

Claim 17. (Original) The method of claim 16 wherein the thrombolytic agent is an anti-platelet agent.

Claim 18. (Original) The method of claim 17 wherein the anti-platelet agent is selected from the group consisting of a salicylate compound, ticlopidine, clopidrogel and a GP IIa/IIIa inhibitor.

Claim 19. (Original) The method of claim 18 wherein the anti-platelet agent is a salicylate compound.


Claim 20. (Original) The method of claim 19 wherein the salicylate compound is aspirin.

Claim 21. (Original) The method of claim 20 wherein the thrombolytic condition is selected from the group consisting of myocardial infarction, stroke, amaurosis fugax, aortic stenosis, cardiac stenosis, coronary stenosis and pulmonary stenosis.

Claim 22. (Presently Amended) The method of claim 15 wherein the compound ~~of claim 1~~ and the thrombolytic agent are administered in a substantially simultaneous manner.

Claim 23. (Presently Amended) The method of claim 15 wherein the compound ~~of claim 1~~ and the thrombolytic agent are administered sequentially.

Claim 24. (Original) An extract of a *Dysidea* sponge comprising a compound having the structure:



or a pharmaceutically acceptable salt, prodrug, tautomer or isomer thereof.